RS
BCYC

R Squared’s Bicycle Therapeutics BCYC Stock Holding History

R Squared’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,057
Closed -$97.7K – 537
2026
Q1 		$97.7K Buy
+21,057
New +$120K 0.05% 371
2025
Q1 		– Sell
-180
Closed -$2.52K – 433
2024
Q4 		$2.52K Buy
+180
New +$3.86K ﹤0.01% 1438

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

R Squared's BCYC Position: Q2 2026 in Review

R Squared sold out of Bicycle Therapeutics (BCYC) in Q2 2026, closing a stake of 21,057 shares — an estimated $97.7K sold.

R Squared first reported a position in BCYC in Q4 2024 and held it in 2 quarters. The position peaked at $97.7K in Q1 2026. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • R Squared reported no remaining Bicycle Therapeutics position as of Q2 2026 after selling out during the quarter.
  • R Squared sold 21,057 Bicycle Therapeutics shares in Q2 2026, an estimated $97.7K.
  • R Squared first reported a position in Bicycle Therapeutics in Q4 2024 and held it in 2 quarters.
  • R Squared's Bicycle Therapeutics position peaked at $97.7K in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.